A phase I study of ADXS-504, a cancer type specific immunotherapy, for patients with biochemically recurrent prostate cancer.
Runcie K, Dallos M, Khan S, Gray J, Marco P, Ping L, LaTourette D, Anderson C, Spina C, Yu J, Deutsch I, Sheeri S, Gutierrez A, Stein M. A phase I study of ADXS-504, a cancer type specific immunotherapy, for patients with biochemically recurrent prostate cancer. Journal Of Clinical Oncology 2022, 40: tps5115-tps5115. DOI: 10.1200/jco.2022.40.16_suppl.tps5115.Peer-Reviewed Original ResearchAndrogen deprivation therapyProstate-specific antigenTumor-associated antigensBiochemical recurrenceProstate cancerRadiation therapyTumor microenvironmentRadical prostatectomyStudy treatmentPromote anti-tumor immune responsesAntigen-specific T cell responsesBiochemical recurrence of prostate cancerBiochemically recurrent prostate cancerCastration sensitive prostate cancerPSA responseTime to PSA progressionDose of study treatmentAnti-tumor immune responseStandard first-line treatmentEvidence of metastatic diseaseMyeloid-derived suppressor cellsImmunosuppressive regulatory T cellsPeptide antigensLive-attenuated Listeria monocytogenesRecurrent prostate cancer